This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

This study has been terminated.
Information provided by:
Mitsubishi Tanabe Pharma Corporation Identifier:
First received: April 29, 2003
Last updated: June 23, 2005
Last verified: June 2005
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.

Condition Intervention Phase
Peripheral Vascular Disease Drug: Ecraprost in lipid emulsion Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia

Resource links provided by NLM:

Further study details as provided by Mitsubishi Tanabe Pharma Corporation:

Primary Outcome Measures:
  • Reduction in proportion of subjects who experience a major amputation.
  • Reduction in proportion of subjects who die within 6 months from treatment initiation.

Secondary Outcome Measures:
  • Reduction in major amputation rate only.
  • Reduction in critical cardiovascular events.
  • Improvement in complete ulcer healing.
  • Improvement in pain at rest.
  • Improvement in quality of life.
  • Improvement in hemodynamic measurements.
  • Improvement in neuropathy.

Estimated Enrollment: 560
Study Start Date: July 2001
Estimated Study Completion Date: June 2004

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Critical leg ischemia (CLI) defined as distal extremity pain at rest, or peripheral ischemic ulcer(s), with severe hemodynamic impairment as diagnosed by ankle systolic pressure, toe systolic pressure or TcPO2
  • The subject has exhausted all standard revascularization treatment options at this time.

Exclusion Criteria:

  • Subjects with a previous major amputation (at or above ankle)
  • Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of < 20 cc/min, or receiving chronic hemodialysis therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00059644

  Show 27 Study Locations
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
  More Information Identifier: NCT00059644     History of Changes
Other Study ID Numbers: WFI 01-01
Study First Received: April 29, 2003
Last Updated: June 23, 2005

Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Ecraprost in lipid emulsion
Critical Limb Ischemia due to peripheral arterial disease

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Pathologic Processes
Cardiovascular Diseases
Arterial Occlusive Diseases processed this record on August 18, 2017